filgrastim [G-CSF] (Neupogen, Lenograstim, Granulokine)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Neupogen.

Biosimilar filgrastim-sndz (Zarxio) FDA-approved March 2015.

Indications

Contraindications

Pregnancy category C

Safety in lactation ?

Dosage

Pharmacokinetics

  • rapidly absorbed after SC administration
  • response is noted in 24 hours; plateau in 3-5 days
  • elimination: 1st order, 1/2 life 3-4 hours
  • pegfilgrastim: action for several weeks

Adverse effects

Mechanism of action

More general terms

More specific terms

References

  1. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  2. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  3. 3.0 3.1 3.2 3.3 3.4 3.5 Medical Knowledge Self Assessment Program (MKSAP) 17, 18, 19 American College of Physicians, Philadelphia 2015, 2018, 2022.
  4. 4.0 4.1 4.2 Myeloid Growth Factors National Comprehensive Cancer Network In: Anello J, Feinberg B, Heinegg J et al New Clinical Practice Guidelines, February 2018. Medscape. February 07, 2018 https://reference.medscape.com/viewarticle/892328
    Crawford J, Becker PS, Armitage JO, et al. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Dec;15(12):1520-41. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29223990 <Internet> http://www.jnccn.org/content/15/12/1520.long
  5. Smith TJ, Bohlke K, Lyman GH et al Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26169616